Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04421664 · ClinicalTrials.gov registry record · Phase 3
Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
A Phase 3 study, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre.
- Terminated
- Registry status
- Phase 3
- Development phase
- 70
- Enrollment target
NCT04421664 is a Phase 3 study that was terminated before completion, run by McGill University Health Centre/Research Institute of the McGill University Health Centre. The registered enrollment target is 70 participants.
The verdict
NCT04421664, a Phase 3 study, was terminated before completion, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 70 participants
- Enrollment target
Study Summary
Study Objective: To test if early preemptive hydroxychloroquine therapy can prevent disease progression in persons with known symptomatic COVID-19 disease, decreasing hospitalizations and symptom severity.
Interventions
- DRUG Placebo oral tablet
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2020-03-25 |
| Est. Completion | 2020-08-17 |
| Phase | Phase 3 |
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre9 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04421664
The ClinicalTrials.gov registry entry for NCT04421664 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is McGill University Health Centre/Research Institute of the McGill University Health Centre, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04421664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04421664 about?
NCT04421664 is a clinical study titled "Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)". Study Objective: To test if early preemptive hydroxychloroquine therapy can prevent disease progression in persons with known symptomatic COVID-19 disease, decreasing hospitalizations and symptom severity.
What is the current status of trial NCT04421664?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 70 participants. The study started on 2020-03-25. Estimated completion is 2020-08-17.
What interventions are being tested in trial NCT04421664?
The interventions under investigation include: Placebo oral tablet (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04421664?
This trial is sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.